Advertisement
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on thedevelopment of compounds for the treatment of cardiovascular disease. VIA isbuilding a pipeline of small-molecule drugs that target a significant unmetmedical need: reducing inflammation in the blood vessel wall, which is anunderlying cause of atherosclerosis and its complications, including heartattack and stroke. The company's lead drug candidate, VIA-2291, is in multiplePhase 2 clinical studies in patients with cardiovascular disease. For moreinformation, visit: http://www.viapharmaceuticals.com.
Advertisement
Forward-Looking Statements
This press release may contain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements relate to future events or to VIA's future financial performanceand involve known and unknown risks, uncertainties and other factors that maycause VIA's actual results, levels of activity, performance or achievements tobe materially different from any future results, levels of activity,performance or achievements expressed or implied by these forward-lookingstatements. In some cases, you can identify forward-looking statements by theuse of words such as "may," "could," "expect," "intend," "plan," "seek,""anticipate," "believe," "estimate," "predict," "potential," "continue" or thenegative of these terms or other comparable terminology. You should not placeundue reliance on forward-looking statements since they involve known andunknown risks, uncertainties and other factors which are, in some cases,beyond VIA's control and which could materially affect actual results, levelsof activity, performance or achievements.
Factors that may cause actual results to differ materially from currentexpectations include, but are not limited to:
All forward-looking statements attributable to us or persons acting on ourbehalf are expressly qualified in their entirety by the cautionary statementsset forth above. Forward-looking statements speak only as of the date they aremade, and VIA undertakes no obligation to update publicly any of thesestatements in light of new information or future events.-- our ability to obtain necessary financing; -- our ability to control our operating expenses; -- our ability to recruit and enroll patients for the ACS and FDG-PET clinical trials; -- failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials; -- our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials; -- complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays; -- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- the outcome of any legal proceedings; -- our ability t
